Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS Raises Profile In Drug Costs Discussion

This article was originally published in The Pink Sheet Daily

Executive Summary

On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.


Related Content

HHS Drug Cost Forum: Merck, Novartis To Represent Industry View
Time Is Now For Shaping CMS Drug Affordability, Innovation Policies – Slavitt
PhRMA Pushing For Policies To Facilitate Outcomes-Based Pricing
Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs
Creative Drug Pricing Hindered By Medicaid Best Price, Stakeholders Say
Congressional Dems Generating Heat, But No Hearings, On Rx Prices
HHS Envisions Drug Price Arbitration For Part D





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts